# Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells

> **NCT04361942** · PHASE2 · COMPLETED · sponsor: **Red de Terapia Celular** · enrollment: 24 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **BIOLOGICAL:** Mesenchymal Stem Cells (MSCs)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04361942
- **Lead sponsor:** Red de Terapia Celular
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-01
- **Primary completion:** 2021-10-28
- **Final completion:** 2021-10-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-02-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361942, "Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04361942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*